GlassScriptPhysician profile
Taryn R Thompson
NPI 1558639567
$9,660.10
in general payments reported to CMS, 2019-2025
56 companies · $2,808 in 2025
The $2,808 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.44 · 2022: $1,793 · 2023: $2,599 · 2024: $2,396 · 2025: $2,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,561 · Travel and Lodging: $454 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $454 · Education: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,560.91 |
| Travel and Lodging | $454.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $454.26 |
| Education | $333.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,133.15 | 2021-2025 | Erleada, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $1,101.20 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $908.52 | 2025 | |
| Eisai INC. | $776.55 | 2022-2025 | |
| Celgene Corporation | $669.92 | 2022-2025 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $651.45 | 2022-2025 | Libtayo |
| Incyte Corporation | $453.33 | 2022-2025 | Monjuvi, Pemazyre, Jakafi |
| Daiichi Sankyo INC. | $385.20 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $305.47 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $296.93 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $291.94 | 2022-2025 | Calquence, Imfinzi, Enhertu |
| Pharmaessentia USA Corporation | $152.53 | 2023-2025 | Besremi |
| Pfizer INC. | $151.40 | 2022-2025 | |
| Amgen INC. | $142.65 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.30 | 2022-2025 | Iclusig, Ninlaro, Alunbrig |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $120.51 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $119.27 | 2023-2025 | Myrisk |
| Abbvie INC. | $115.07 | 2024-2025 | |
| Beigene USA, INC. | $111.16 | 2022-2025 | Brukinsa |
| Seagen INC. | $99.99 | 2025 | |
| Genmab U.S., INC. | $99.60 | 2023-2025 | Epkinly |
| Genentech USA, INC. | $97.45 | 2023-2025 | Polivy, Lunsumio, Itovebi |
| Caris Mpi, INC. | $93.85 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $92.06 | 2023-2025 | Quzyttir, Xermelo, Zoladex |
| Lilly USA, LLC | $91.83 | 2021-2025 | Verzenio, Retevmo, Jaypirca |
| Taiho Oncology, INC. | $84.40 | 2023-2025 | |
| Adc Therapeutics America, INC. | $77.48 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $76.16 | 2023-2025 | Monoferric, Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $71.61 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Sumitomo Pharma America, INC. | $61.18 | 2024 | Orgovyx |
| Servier Pharmaceuticals LLC | $54.47 | 2025 | |
| Emd Serono, INC. | $41.06 | 2022-2024 | |
| Myovant Sciences INC. | $37.44 | 2022 | |
| Mirati Therapeutics, INC. | $35.19 | 2023-2024 | Krazati |
| Immunogen, INC. | $32.49 | 2023 | Elahere |
| Rigel Pharmaceuticals, INC. | $32.41 | 2022 | |
| Deciphera Pharmaceuticals INC. | $30.90 | 2024 | Qinlock |
| Beone Medicines USA, INC. | $30.86 | 2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $30.63 | 2022-2023 | Fotivda |
| Puma Biotechnology, INC. | $29.58 | 2023-2024 | |
| Apellis Pharmaceuticals, INC. | $28.97 | 2023-2024 | Empaveli |
| Karyopharm Therapeutics INC. | $28.84 | 2023 | Xpovio |
| Cumberland Pharmaceuticals, INC. | $28.55 | 2024-2025 | Sancuso |
| Novocure INC. | $24.06 | 2025 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.23 | 2024 | |
| Exelixis INC. | $18.90 | 2023 | Cabometyx |
| Novo Nordisk INC | $15.23 | 2025 | |
| Agios Pharmaceuticals, INC. | $14.30 | 2025 | Pyrukynd |
| Array Biopharma INC | $13.96 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.46 | 2023 | Ultomiris |
| Spectrum Pharmaceuticals INC. | $13.20 | 2024 | Rolvedon |
| Stemline Therapeutics INC. | $12.92 | 2023 | Orserdu |
| Epizyme, INC. | $12.26 | 2022 | |
| Veracyte, INC. | $12.24 | 2023 | |
| Coherus Oncology, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taryn Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.